Takeda completes sale of select otc and non-core assets to hypera pharma

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced the completion of its previously-announced sale of a portfolio of select products sold in latin america to hypera s.a. (“hypera pharma”) for a total value of $825 million usd. this divestment agreement was first announced in march 2020. the divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in brazil, mexico, and other south american,
TAK Ratings Summary
TAK Quant Ranking